Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc develops clinical-stage medicines based on its proprietary bicyclic peptide, or Bicycle®, technology. Its updates center on oncology programs using fully synthetic constrained peptides, including nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2; zelenectide pevedotin, a Bicycle Drug Conjugate targeting Nectin-4; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137; and Bicycle Radioconjugates for radiopharmaceutical use.
Recurring news includes clinical and preclinical data presentations, oncology pipeline updates, financial results, leadership changes, and collaborations that support radioisotope and radiopharmaceutical supply. Company announcements also discuss work with partners in additional therapeutic areas and the structure of its U.K. and U.S. operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bicycle Therapeutics plc (NASDAQ: BCYC) has announced its participation in the 2023 American Association for Cancer Research (AACR) Annual Meeting, scheduled from April 14-19, 2023 in Orlando, FL. The company will present four posters highlighting its innovative bicyclic peptide technology aimed at enhancing cancer treatment.
The presentations include:
- NK-TICA™ Agonist - Modulation of natural killer cell immune response on April 17.
- In Vivo Models for NK-TICA™ - Evaluation of a novel immune cell agonist on April 17.
- BT7455 - Anti-tumor efficacy study on April 17.
- BT7480 - Phase 1/2 study on April 18.
Further details will be available post-presentation on bicycletherapeutics.com.
ResearchAndMarkets.com has released the report "Global Genetic Disorders Partnering 2016-2023," providing a comprehensive overview of genetic disorder deals signed worldwide since 2016. The report captures key aspects including deal trends, financial terms, and the most active dealmakers in the biopharma industry. It includes detailed analyses of deal structures, contract documents, and financial metrics, such as headline values, upfront payments, and royalty rates. Covering multiple genetic disorders like Cystic Fibrosis and Huntington's Disease, this report aims to be an essential resource for stakeholders in genetic disorder collaborations.
The report titled Global Cardiovascular Partnering 2016-2023, released by ResearchAndMarkets.com, analyzes cardiovascular disease deals from major pharmaceutical and biotechnology firms worldwide since 2016. Key insights include trends in cardiovascular partnering, financial deal terms, and structures.
It evaluates over 850 cardiovascular deals, detailing upfront payments, milestone payments, and royalties. The report is segmented to provide valuable benchmarking and analysis, including an overview of leading dealmakers and the financial metrics of significant agreements. This resource aims to inform prospective dealmakers in cardiovascular technology and product commercialization.
Bicycle Therapeutics (NASDAQ: BCYC) has appointed Santiago Arroyo, M.D., Ph.D., as Chief Development Officer effective March 31. Dr. Arroyo brings over 20 years of experience, having previously served as Chief Medical Officer at Momenta Pharmaceuticals. He will oversee the clinical development of Bicycle’s expanding pipeline, including programs in oncology. Jennifer Perry, Pharm.D., has been promoted to Senior Vice President, Commercial, with over 15 years of experience in oncology. The transition includes the departure of Chief Medical Officer Dr. Dominic Smethurst. These leadership changes aim to position Bicycle for continued growth and success in late-stage development.
Bicycle Therapeutics has announced a strategic collaboration with Novartis to develop targeted radioligand therapies for oncology. Under this agreement, Bicycle will receive a $50 million upfront payment and potential milestone payments totaling up to $1.7 billion. Novartis will manage the further development and commercialization of the BRCs, funding all associated costs. This partnership aims to leverage Bicycle's proprietary technology in the creation of precision-guided radiopharmaceuticals, enhancing its clinical development efforts in cancer treatment.
Bicycle Therapeutics (NASDAQ: BCYC) announced participation in two investor conferences in March 2023. The company will host a fireside chat at Cowen's 43rd Annual Health Care Conference on March 7 at 9:50 a.m. ET, and at the Barclays Global Healthcare Conference on March 16 at 9:00 a.m. ET. Live webcasts of these discussions will be available on the company's website, with archived replays accessible for 90 days post-event. Bicycle Therapeutics specializes in developing a new class of therapeutics using its proprietary Bicycle technology, targeting underserved diseases with high-affinity and selectivity.